MGMT and glioblastoma: In addition, subgroups of GBM patients with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation have been shown to have a better prognosis and benefit from more aggressive initial therapy with TMZ and lomustine.10–12 As such, while recent advances in molecular pathology may allow for more individualised treatment in some patients, many patients with GBM do not benefit, and new treatments are urgently required.